Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;9(3):171-181.
doi: 10.1177/1758834016679942. Epub 2016 Dec 11.

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Camille Mazza  1 , Bernard Escudier  2 , Laurence Albiges  3
Affiliations
Review

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Camille Mazza et al. Ther Adv Med Oncol. 2017 Mar.

Abstract

Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-α) being the first approved treatments in the 1990s. However, these therapies were effective in only 10-20% of cases and were not well tolerated. Recently, new insights on the interaction between the immune system and tumor have identified the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway to be a key player in evading host immune responses. The strategy of immune checkpoint blockade is to reduce inhibitory signaling and restore the patient's natural tumor-specific T-cell-mediated immune responses. Nivolumab is the first PD-1 inhibitor to have gained approval for the treatment of patients with metastatic melanoma, squamous and nonsquamous non-small cell lung cancer (NSCLC), Hodgkin disease and recently RCC. In this review, we discuss results from studies of nivolumab in RCC, clinical experience with this agent, and its future development.

Keywords: immune checkpoint inhibitor; immunotherapy; nivolumab; programmed death-1; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abe H., Kamai T. (2013) Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol 20: 944–955. - PubMed
    1. Al-Marrawi M., Rini B., Harshman L., Bjarnason G., Wood L., Vaishampayan U., et al. (2013) The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 8: 203–209. - PMC - PubMed
    1. Amin A., Plimack E., Infante J., Ernstoff M., Rini B., McDermot D., et al. (2014) Nivolumab in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 32: abstract 5010.
    1. Ascierto P., Addeo R., Cartenì G., Daniele B., De Laurentis M., Ianniello, et al. (2014) The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med 12: 291. - PMC - PubMed
    1. Choueiri T., Escudier B., Powles T., Mainwaring P., Rini B., Donskov F., et al. (2015a) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1814–1823. - PMC - PubMed